Clinical trials: Chronic Insomnia Disorder
Chronic Primary Insomnia
Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia
A 2-night polysomnography / 5-way cross-over study to evaluate the effect, safety and tolerability of oral administration of almorexant (ACT 078573) in elderly subjects with primary insomnia.
- Trial name
- NCT00606593
- Where
- 21 sites in United States
- Volunteers
- 112 people
- Sponsor
- Midnight Pharma, LLC
Sleep Initiation and Maintenance Disorders, Mental Disorders
A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)
To investigate the long-term efficacy and safety of treatment with esmirtazapine (Org 50081, SCH 900265, MK-8265) compared to placebo, in participants with chronic primary insomnia.
- Conditions
- Sleep Initiation and Maintenance Disorders, Mental Disorders, Dyssomnias, Sleep Disorders
- Trial name
- NCT00631657
- Testing
- Esmirtazapine
- Volunteers
- 460 people
- Sponsor
- Merck Sharp & Dohme LLC
Sleep Initiation and Maintenance Disorders
Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia
The purpose of this study is to determine the efficacy of ramelteon, once daily (QD), combined with doxepin in treating subjects with insomnia.
- Trial name
- NCT00755495
- Testing
- Ramelteon and doxepin, Ramelteon, Doxepin
- Volunteers
- 472 people
- Sponsor
- Takeda
Insomnia
Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)
The purpose of this study is to determine if esmirtazapine (Org 50081) is a safe and effective treatment for insomnia. It was anticipated that esmirtazapine would increase mean Total Sleep Time (TST) as recorded in sleep diaries…
- Trial name
- RUBY (NCT00482612)
- Testing
- Esmirtazapine
- Volunteers
- 526 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Insomnia
A Remote, 9-week Insomnia Treatment Trial to Collect Real World Data for a Digital Therapeutic
The purpose of the study is to collect data in a real-world environment, for a digital therapeutic that delivers CBT-I through a decentralized clinical trial, open to participants with chronic insomnia.
- Trial name
- DREAM (NCT04325464)
- Testing
- PEAR-003A
- Where
- United States
- Volunteers
- 1,590 people
- Sponsor
- Pear Therapeutics, Inc.
Insomnia
Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)
This study will evaluate the safety, tolerability, and effect of multiple doses of suvorexant (MK-4305) on respiratory function in participants with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01293006
- Testing
- suvorexant
- Volunteers
- 25 people
- Sponsor
- Merck Sharp & Dohme LLC
Post-Concussion Symptoms, Insomnia
Neurotechnology Following Traumatic Brain Injury
This two-part study seeks to improve symptoms such as pain and sleep problems after concussion, or mild traumatic brain injury (mTBI).
- Conditions
- Post-Concussion Symptoms, Insomnia, Pain, Chronic, Depressive Symptoms
- Trial name
- Cereset (NCT03649958)
- Testing
- HIRREM-SOP or Cereset, Cereset 2x
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Brain State Technologies, LLC
Chronic Insomnia
Efficacy and Safety of Ramelteon on Chronic Insomnia
The purpose of this study is to determine the dose response of Ramelteon, once daily (QD), in Japanese subjects with Chronic Insomnia
- Trial name
- NCT00915135
- Volunteers
- 66 people
- Sponsor
- Takeda